The purpose of this study is to look at the safety and effectiveness of PAXLOVID in thereal world and not in clinical studies. The study observes patients who have a highchance of getting severe COVID-19 in Korea.This study is seeking participants who are: - Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death. - Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. - Patients who have signed informed consent documents after understanding all the important parts of the study.All participants are treated according to routine medical practice and there are noscheduled visits required by this study. All participants will be studied for a follow-upperiod of 28 days from the last PAXLOVID treatment to understand the safety and theeffectiveness of treatment.
Not Provided
Inclusion Criteria:
- Patients who received, are currently receiving, or are going to receive PAXLOVID
according to locally approved label.
- Patients (or a legally acceptable representative) who are willing to provide written
informed consent/assent prior to study enrollment.
Exclusion Criteria:
- Patients with contraindication according to locally approved label of PAXLOVID.
- Patients who are going to receive any investigational medicine during the
observation period.
Pfizer Korea
Seoul, Korea, Republic of
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Pfizer CT.gov Call Center, Study Director
Pfizer